Anti-Rat β-2-Microglobulin (Clone 4C9) – Purified No Carrier Protein
Anti-Rat β-2-Microglobulin (Clone 4C9) – Purified No Carrier Protein
Product No.: B615
- -
- -
Clone 4C9 Target β-2-Microglobulin Formats AvailableView All Product Type Hybridoma Monoclonal Antibody
Alternate Names β2M Isotype Mouse IgG1 κ Applications FA |
- -
- -
Antibody DetailsProduct DetailsReactive Species Rat Host Species Mouse Immunogen Soluble neonatal Fc receptor (FcRn) Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. State of Matter Liquid Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month.
For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? FA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity 4C9 activity is directed against rat β-2-microglobulin that is free or complexed with
the FcRn heavy chain.
Background Neonatal Fc receptor (FcRn) is a 52 kDa membrane bound heterodimeric glycoprotein composed of a heavy and light chain, with the latter being β-2-microglobulin1. FcRn plays a role in the regulation of IgG catabolism and is located in the endosome where it binds to Fc and IgG. β-2- microglobulin also associates with class I major histocompatibility complex molecules, which are structurally similar to FcRn2. In this capacity, β-2-microglobulin plays an important role in tumor antigen presentation and immune surveillance3. 4C9 was generated by immunizing BALB/c mice with soluble FcRn2. Splenocytes were fused with HL-1 murine myeloma cells. 4C9 is able to bind to β-2-microglobulin as well as FcRn heterodimers in ELISA tests, can immunoprecipitate soluble FcRn heterodimers, and can also stain lipid-linked rat β-2-microglobulin (β2m-DAF), truncated FcRn heavy chain paired with β2m-DAF, and lipid-linked FcRn heavy chain paired with unaltered β-2-microglobulin. 4C9 blocks binding of IgG to FcRn in vitro2 and FcRn blockade has been shown to have a positive effect on IgG-mediated autoimmune diseases1. In support of this, 4C9 induces a transient and dose-dependent increase in the elimination of exogenously administered antimethotrexate IgG in rats4. Antigen Distribution β-2-microglobulin has cytoplasmic and membranous expression in most
cell types and can be secreted to blood.
Ligand/Receptor Leukocytes, platelets, endothelial cells and epithelial cells NCBI Gene Bank ID Research Area Immunology References & Citations1 Low SC, Mezo AR. AAPS J. 11(3):432-434. 2009. 2 Raghavan M, Chen MY, Gastinel LN, et al. Immunity. 1(4):303-315. 1994. 3 Wang H, Liu B, Wei J. Cancer Lett. 517:96-104. 2021. 4 Getman KE, Balthasar JP. J Pharm Sci. 94(4):718-729. 2005. |
Formats Available
- -
- -
